COVID-19, Wide Spread and Treatment Need | ||||
| Bulletin of Egyptian Society for Physiological Sciences | ||||
| Article 1, Volume 42, Issue 1, January 2022, Page 1-10 PDF (305.41 K) | ||||
| Document Type: Review Article | ||||
| DOI: 10.21608/besps.2021.51022.1086 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Eman Salah El-Shafey   1; Eslam Samy Elsherbiny2
| ||||
| 1Damietta University Faculty of Science | ||||
| 2Damietta university Faculty of Science | ||||
| Abstract | ||||
| Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia linked to rapid replication of the virus and worldwide spread. Originating in Wuhan China December 2019, the current COVID-19 epidemic has grown rapidly with individual-to-person infection expanding to become a pandemic-scale global health emergency. As a pandemic, COVID-19 has led many researchers from various areas of biomedicine to pursue approaches or therapies to handle the pandemic. COVID-2019 cure is in part based on the patient's own immune system. When the over-activated immune system kills the virus, a large number of inflammatory factors are produced which lead to severe cytokine storms. This appears that the key explanation for damage to these organs may be due to a cytokine storm caused by the virus. Current therapies available-including non-specific anti-viral, antibiotics to treat secondary bacterial infections and sepsis, and inflammatory corticosteroids-fail in serious disease where the hallmark is the COVID-19-induced cytokine storm in the lung. Until now, however, no specific treatment has been found for this disease. Thus, there is a significant unmet need for safe and efficient care. | ||||
| Keywords | ||||
| COVID-19; Immunomodulatory; Cytokine storms; Treatment; Investigational Drugs | ||||
|
Statistics Article View: 163 PDF Download: 106 |
||||
